Previous 10 |
Ipsen and Servier announce initial Phase II/III clinical data evaluating investigational liposomal irinotecan (ONIVYDE®) as a second-line treatment for small cell lung cancer (SCLC) at the IASLC 2019 World Conference on Lung Cancer Canada NewsWire MONTREAL, Sept. 10, 2019 ...
Ipsen and Servier announce initial Phase 1/2 clinical data evaluating liposomal irinotecan (ONIVYDE®) as an investigational first-line treatment for metastatic pancreatic cancer at ESMO 21st World Congress on Gastrointestinal Cancer Canada NewsWire LAVAL, QC, July 5, 2019 ...
New authorisation recognises the role of non-medical injectors (NMIs) such as physiotherapists in focal spasticity and advances standards of care SLOUGH, England , June 5, 2019 /PRNewswire/ -- Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Medicines and Healthcare Products...
News, Short Squeeze, Breakout and More Instantly...
SPDR S&P International Industrial Sector Company Name:
IPN Stock Symbol:
NYSE Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC) Canada NewsWire Bylvay (odevixibat) is the first and only oral treatment available in Canada ...